Thomas [Analyst]'s questions to Bio-Techne Corp (TECH) leadership • Q1 2025
Question
An analyst from NewfronResearch asked for clarity on the drivers behind the Q2 outlook of mid-single-digit growth, given an easier comparison, and inquired about the company's expectations for a calendar year-end budget flush.
Answer
CFO Jim Hippel explained that the Q2 outlook considers headwinds from the timing of holidays this year. He anticipates stable performance from the pharma and academic markets, with some moderation in the exceptional Q1 cell and gene therapy growth being offset by gaining momentum in the broader RUO biotech business. Regarding a budget flush, Hippel stated it's not a major factor for Bio-Techne but noted that while there's potential for a pharma CapEx flush, the company is not hearing that from the field and considers it 'less likely than more likely' at this time.